Griffiths C E, Kang S, Ellis C N, Kim K J, Finkel L J, Ortiz-Ferrer L C, White G M, Hamilton T A, Voorhees J J
Department of Dermatology, University of Michigan Medical Center, Ann Arbor, USA.
Arch Dermatol. 1995 Sep;131(9):1037-44.
The efficacy of topical tretinoin (all-trans-retinoic acid) in treating photoaging is well established. Questions that remain are (1) whether irritation causes all or part of the improvement; (2) the concentration of tretinoin that maximizes clinical response with minimal side effects; and (3) the effects of long-term treatment on components of the cutaneous immune system. To address these issues, 99 photoaged patients completed a 48-week study using 0.1% tretinoin cream (n = 32), 0.025% tretinoin (n = 35), or vehicle (n = 32) once daily in a double-blind manner. Before and after treatment, we assessed histologic features, keratinocyte expression of HLA-DR and intercellular adhesion molecule-1, numbers of epidermal Langerhans' cells and epidermal and dermal T lymphocytes, and vascularity as measured by dermal endothelial cell area.
Both 0.1% and 0.025% tretinoin produced statistically significant overall improvement in photoaging of the face compared with vehicle; there were no clinically or statistically significant differences in efficacy between the two concentrations of tretinoin. After 48 weeks, 0.1% and 0.025% tretinoin produced similar statistically significant epidermal thickening (by 30% and 28%, respectively) compared with vehicle (11% decrease) and increased vascularity (by 100% and 89%, respectively) compared with vehicle (9% decrease). By various analyses, irritant side effects (erythema and scaling) were statistically significantly greater with 0.1% tretinoin than with 0.025% tretinoin. No significant changes occurred in any immunologic markers when tretinoin and vehicle treatments were compared.
Tretinoin 0.1% and 0.025% produce similar clinical and histologic changes in patients with photoaging, despite significantly greater incidence of irritation with the higher concentration. The separation between clinical improvement and irritation suggests that mechanisms other than irritation dominate tretinoin-induced repair of photoaging in humans.
外用维甲酸(全反式维甲酸)治疗光老化的疗效已得到充分证实。仍存在的问题包括:(1)炎症是否导致了全部或部分改善;(2)能使临床反应最大化且副作用最小的维甲酸浓度;以及(3)长期治疗对皮肤免疫系统成分的影响。为解决这些问题,99名光老化患者以双盲方式完成了一项为期48周的研究,其中32名患者每日使用0.1%维甲酸乳膏,35名患者每日使用0.025%维甲酸,32名患者每日使用赋形剂。治疗前后,我们评估了组织学特征、角质形成细胞HLA - DR和细胞间黏附分子 - 1的表达、表皮朗格汉斯细胞以及表皮和真皮T淋巴细胞的数量,并用真皮内皮细胞面积测量血管分布情况。
与赋形剂相比,0.1%和0.025%的维甲酸均使面部光老化有统计学意义的总体改善;两种浓度的维甲酸在疗效上无临床或统计学显著差异。48周后,与赋形剂(降低11%)相比,0.1%和0.025%的维甲酸分别使表皮增厚有统计学意义的相似增加(分别为30%和28%),与赋形剂(降低9%)相比,血管分布增加(分别为100%和89%)。通过各种分析,0.1%维甲酸引起的刺激性副作用(红斑和脱屑)在统计学上显著大于0.025%维甲酸。比较维甲酸和赋形剂治疗时,任何免疫标志物均未发生显著变化。
0.1%和0.025%的维甲酸在光老化患者中产生相似的临床和组织学变化,尽管较高浓度的刺激性发生率显著更高。临床改善与炎症之间的分离表明,除炎症外的其他机制主导了维甲酸诱导的人类光老化修复。